Screener / SEC EDGAR /CIK 0001321732 /10-K filed Feb 25, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Penumbra Inc PEN

Compare with peers Embed
Earnings releases

Latest results release: Oct 29, 2026

8-K item 2.02, exhibit 99

What PEN's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

What the company says its adjusted numbers leave out:

We consider non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, the excess tax benefits associated with share-based compensation arrangements, and expenses related to certain litigation matters that we have determined are not a normal or recurring part of our business, including settlement costs and legal fees. release Apr 23, 2025

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 29, 2026 · EX-99.1

Penumbra, Inc. Reports Third Quarter 2026 Financial Results

Open on SEC

ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.

Revenue of $410.1 million in the third quarter of 2026, an increase of 15.6% compared to the third quarter of 2025.

Global thrombectomy revenue of $279.2 million in the third quarter of 2026, an increase of 18.1% compared to the third quarter of 2025. U.S. VTE revenue increased 26.0% compared to the same period a year ago.

Global embolization and access revenue of $131.0 million in the third quarter of 2026, an increase of 10.8% compared to the third quarter of 2025.

U.S. neuro revenue of $77.9 million in the third quarter of 2026, an increase of 19.3% compared to the third quarter of 2025.

Gross profit margin of 68.3% in the third quarter of 2026, an increase of 0.5% compared to the third quarter of 2025.

Total operating expenses of $229.6 million in the third quarter of 2026, comprised of R&D of $25.4 million and SG&A of $204.2 million, which includes $7.1 million of acquisition-related expenses associated with the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation.

Income from operations of $50.7 million and net income of $42.3 million in the third quarter of 2026.

Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation (NYSE: BSX), the Company will not be providing financial guidance for the full year 2026 or hosting a conference call to discuss financial results for the three months ended September 30, 2026.

Penumbra, Inc., the world’s leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X .

Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained; potential adverse effects to our business during the pendency of the acquisition, such as employee departures or diversion of management’s attention from our business; failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 25, 2026. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking 1 statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. 2

September 30, 2026 December 31, 2025 ────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash equivalents $ 254,282 $ 186,897 Marketable investments 419,330 357,919 Accounts receivable, net 195,216 190,021 Inventories 459,132 431,549 Prepaid expenses and other current 48,671 50,298 assets Total current assets 1,376,631 1,216,684 Property and equipment, net 156,443 117,436 Operating lease 164,346 173,587 right-of-use assets Finance lease right-of-use 23,510 25,972 assets Intangible assets, net 5,549 6,186 Goodwill 166,479 166,750 Deferred taxes 79,221 79,188 Other non-current assets 52,924 40,716 Total assets $ 2,025,103 $ 1,826,519 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 41,961 $ 34,736 Accrued liabilities 174,767 132,163 Current operating lease 14,706 13,841 liabilities Current finance lease 2,376 2,393 liabilities Total current liabilities 233,810 183,133 Non-current operating lease 173,277 182,751 liabilities Non-current finance lease 19,031 20,714 liabilities Other non-current 15,476 12,318 liabilities Total liabilities 441,594 398,916 Stockholders’ equity: Common stock 39 39 Additional paid-in capital 1,236,068 1,185,525 Accumulated other 37 4,348 comprehensive income Retained earnings 347,365 237,691 Total stockholders’ equity 1,583,509 1,427,603 Total liabilities and stockholders’ $ 2,025,103 $ 1,826,519 equity

Full text with the tables
                                                                                
  Exhibit 99.1                                                                  
                                                                                
                                                                                
          Penumbra, Inc. Reports Third Quarter 2026 Financial Results           
                                                                                
ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the
world’s leading thrombectomy company, today reported financial results for the
third quarter ended September 30, 2026.
                                                                                
  •                                                                             
                                                                                
Revenue of $410.1 million in the third quarter of 2026, an increase of 15.6%
compared to the third quarter of 2025.
                                                                                
  •                                                                             
                                                                                
Global thrombectomy revenue of $279.2 million in the third quarter of 2026, an
increase of 18.1% compared to the third quarter of 2025. U.S. VTE revenue
increased 26.0% compared to the same period a year ago.
                                                                                
  •                                                                             
                                                                                
Global embolization and access revenue of $131.0 million in the third quarter of
2026, an increase of 10.8% compared to the third quarter of 2025.
                                                                                
  •                                                                             
                                                                                
U.S. neuro revenue of $77.9 million in the third quarter of 2026, an increase of
19.3% compared to the third quarter of 2025.
                                                                                
  •                                                                             
                                                                                
Gross profit margin of 68.3% in the third quarter of 2026, an increase of 0.5%
compared to the third quarter of 2025.
                                                                                
  •                                                                             
                                                                                
Total operating expenses of $229.6 million in the third quarter of 2026,
comprised of R&D of $25.4 million and SG&A of $204.2 million, which includes
$7.1 million of acquisition-related expenses associated with the pending
acquisition of Penumbra, Inc. by Boston Scientific Corporation.
                                                                                
  •                                                                             
                                                                                
Income from operations of $50.7 million and net income of $42.3 million in the
third quarter of 2026.

Full Year 2026 Financial Outlook and Webcast and Conference Call Information

Given the pending acquisition of Penumbra, Inc. by Boston Scientific Corporation
(NYSE: BSX), the Company will not be providing financial guidance for the full
year 2026 or hosting a conference call to discuss financial results for the
three months ended September 30, 2026.
                                                                                
  About Penumbra                                                                
                                                                                
Penumbra, Inc., the world’s leading thrombectomy company, is focused on
developing the most innovative technologies for challenging medical conditions
such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and
acute limb ischemia. Our broad portfolio, which includes computer assisted
vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe
with speed, safety and simplicity. By pioneering these innovations, we support
healthcare providers, hospitals and clinics in more than 100 countries, working
to improve patient outcomes and quality of life. For more information, visit
www.penumbrainc.com and connect on Instagram, LinkedIn, and X .
                                                                                
  Forward-Looking Statements                                                    
                                                                                
Except for historical information, certain statements in this press release are
forward-looking in nature and are subject to risks, uncertainties and
assumptions about us. Our business and operations are subject to a variety of
risks and uncertainties and, consequently, actual results may differ materially
from those projected by any forward-looking statements. Factors that could cause
actual results to differ from those projected include, but are not limited to:
the risk that the pending acquisition by Boston Scientific Corporation will not
be completed in the expected timeframe or at all, including the risk that
required regulatory approvals will not be obtained; potential adverse effects to
our business during the pendency of the acquisition, such as employee departures
or diversion of management’s attention from our business; failure to sustain or
grow profitability or generate positive cash flows; failure to effectively
introduce and market new products; delays in product introductions; significant
competition; inability to further penetrate our current customer base, expand
our user base and increase the frequency of use of our products by our
customers; inability to achieve or maintain satisfactory pricing and margins;
manufacturing difficulties; permanent write-downs or write-offs of our inventory
or other assets; product defects or failures; unfavorable outcomes in clinical
trials; inability to maintain our culture as we grow; fluctuations in foreign
currency exchange rates; potential adverse regulatory actions; and the potential
impact of any acquisitions, mergers, dispositions, joint ventures or investments
we may make. These risks and uncertainties, as well as others, are discussed in
greater detail in our filings with the Securities and Exchange Commission
("SEC"), including our Annual Report on Form 10-K for the year ended December
31, 2025 filed with the SEC on February 25, 2026. There may be additional risks
of which we are not presently aware or that we currently believe are immaterial
which could have an adverse impact on our business. Any forward-looking
                                       1                                        
statements are based on our current expectations, estimates and assumptions
regarding future events and are applicable only as of the dates of such
statements. We make no commitment to revise or update any forward-looking
statements in order to reflect events or circumstances that may change.
                                       2                                        
                                                                                
                                 Penumbra, Inc.                                 
                                                                                
                                                                                
                     Condensed Consolidated Balance Sheets                      
                                                                                
                                  (unaudited)                                   
                                                                                
                                 (in thousands)                                 
                                                                                
                                    September 30, 2026       December 31, 2025  
 ────────────────────────────────────────────────────────────────────────────── 
  Assets                                                                        
  Current assets:                                                               
  Cash and cash equivalents      $             254,282    $            186,897  
  Marketable investments                       419,330                 357,919  
  Accounts receivable, net                     195,216                 190,021  
  Inventories                                  459,132                 431,549  
  Prepaid expenses and other                                                    
  current                                       48,671                  50,298  
  assets                                                                        
  Total current assets                       1,376,631               1,216,684  
  Property and equipment, net                  156,443                 117,436  
  Operating lease                              164,346                 173,587  
  right-of-use assets                                                           
  Finance lease right-of-use                    23,510                  25,972  
  assets                                                                        
  Intangible assets, net                         5,549                   6,186  
  Goodwill                                     166,479                 166,750  
  Deferred taxes                                79,221                  79,188  
  Other non-current assets                      52,924                  40,716  
  Total assets                   $           2,025,103    $          1,826,519  
  Liabilities and                                                               
  Stockholders’ Equity                                                          
  Current liabilities:                                                          
  Accounts payable               $              41,961    $             34,736  
  Accrued liabilities                          174,767                 132,163  
  Current operating lease                       14,706                  13,841  
  liabilities                                                                   
  Current finance lease                          2,376                   2,393  
  liabilities                                                                   
  Total current liabilities                    233,810                 183,133  
  Non-current operating lease                  173,277                 182,751  
  liabilities                                                                   
  Non-current finance lease                     19,031                  20,714  
  liabilities                                                                   
  Other non-current                             15,476                  12,318  
  liabilities                                                                   
  Total liabilities                            441,594                 398,916  
  Stockholders’ equity:                                                         
  Common stock                                      39                      39  
  Additional paid-in capital                 1,236,068               1,185,525  
  Accumulated other                                 37                   4,348  
  comprehensive income                                                          
  Retained earnings                            347,365                 237,691  
  Total stockholders’ equity                 1,583,509               1,427,603  
  Total liabilities and                                                         
  stockholders’                  $           2,025,103    $          1,826,519  
  equity                                                                        
                                                                                
                                       3                                        
                                                                                
                                 Penumbra, Inc.                                 
                                                                                
                                                                                
                Condensed Consolidated Statements of Operations                 
                                                                                
                                  (unaudited)                                   
                                                                                
               (in thousands, except share and per share amounts)               
                                                                                
                     Three                               Nine                   
                    Months                             Months                   
                     Ended                              Ended                   
                  Septemb…                           Septemb…                   
            2026       30,    2025             2026       30,    2025           
 ────────────────────────────────────────────────────────────────────────────── 
  Reven…    $      410,145    $     354,685    $     1,174,9…    $     1,018,…  
  Cost                                                                          
  of               129,842          114,269           376,291          337,971  
  reven…                                                                        
  Gross            280,303          240,416           798,658          680,309  
  profit                                                                        
  Opera…                                                                        
  expen…                                                                        
  Resea…                                                                        
  and               25,361           22,677            73,139           67,972  
  devel…                                                                        
  Sales,                                                                        
  gener…           204,203          168,901           595,507          482,321  
  and                                                                           
  admin…                                                                        
  Total                                                                         
  opera…           229,564          191,578           668,646          550,293  
  expen…                                                                        
  Income                                                                        
  from              50,739           48,838           130,012          130,016  
  opera…                                                                        
  Inter…                                                                        
  and                                                                           
  other              5,577            3,487            14,179           11,477  
  incom…                                                                        
  net                                                                           
  Income                                                                        
  before            56,316           52,325           144,191          141,493  
  income                                                                        
  taxes                                                                         
  Provi…                                                                        
  for               14,037            6,474            34,517           11,149  
  income                                                                        
  taxes                                                                         
  Net       $       42,279    $      45,851    $      109,674    $     130,344  
  income                                                                        
  Net                                                                           
  income                                                                        
  per                                                                           
  share:                                                                        
  Basic     $         1.07    $        1.17    $         2.79    $        3.36  
  Dilut…    $         1.07    $        1.17    $         2.77    $        3.32  
  Weigh…                                                                        
  avera…                                                                        
  shares                                                                        
  outst…                                                                        
  Basic           39,402,…          39,078…          39,344,…          38,827…  
  Dilut…          39,620,…          39,302…          39,598,…          39,250…  
                                                                                
                                       4                                        
                                                                                
                                 Penumbra, Inc.                                 
                                                                                
             Reconciliation of Revenue Growth by Geographic Regions             
                                                                                
                                  (unaudited)                                   
                                                                                
                     (in thousands, except for percentages)                     
                                                                                
               Three                                                            
              Months                                                            
               Ended                                                            
             Septem…                                                            
                 30,                              Change                        
 ────────────────────────────────────────────────────────────────────────────── 
                2026             2025             $                 %           
  United           $  324,248       $  275,029    $       49,219       17.9  %  
  States                                                                        
  Intern…              85,897           79,656             6,241        7.8  %  
  Total            $  410,145       $  354,685    $       55,460       15.6  %  
                                                                                
                                                                                
               Nine                                                             
             Months                                                             
              Ended                                                             
            Septem…                                                             
                30,                              Change                         
 ────────────────────────────────────────────────────────────────────────────── 
               2026             2025             $                  %           
  United          $  926,080       $  792,707    $       133,373       16.8  %  
  States                                                                        
  Inter…             248,869          225,573             23,296       10.3  %  
  Total           $  1,174,…       $  1,018,…    $       156,669       15.4  %  
                                                                                
                                                                                
                                 Penumbra, Inc.                                 
                                                                                
             Reconciliation of Revenue Growth by Product Categories             
                                                                                
                                  (unaudited)                                   
                                                                                
                     (in thousands, except for percentages)                     
                                                                                
               Three                                                            
              Months                                                            
               Ended                                                            
             Septem…                                                            
                 30,                              Change                        
 ────────────────────────────────────────────────────────────────────────────── 
                2026             2025             $                 %           
  Thromb…          $  279,157       $  236,422    $       42,735       18.1  %  
  Emboli…                                                                       
  and                 130,988          118,263            12,725       10.8  %  
  Access                                                                        
  Total            $  410,145       $  354,685    $       55,460       15.6  %  
                                                                                
                                                                                
               Nine                                                             
             Months                                                             
              Ended                                                             
            Septem…                                                             
                30,                              Change                         
 ────────────────────────────────────────────────────────────────────────────── 
               2026             2025             $                  %           
  Throm…          $  792,055       $  693,222    $        98,833       14.3  %  
  Embol…                                                                        
  and                382,894          325,058             57,836       17.8  %  
  Access                                                                        
  Total           $  1,174,…       $  1,018,…    $       156,669       15.4  %  
                                                                                
                                                                                
  Investor Relations                                                            
                                                                                
Penumbra, Inc.

[email protected]

Source: Penumbra, Inc.
                                       5                                        

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PEN/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.